2. Signaling Pathways
  3. Apoptosis
    Metabolic Enzyme/Protease
  4. Glutathione Peroxidase

Glutathione Peroxidase

Glutathione Peroxidase

Related Products

PDF 0.33 MB

Glutathione peroxidases (GPx) are a family of enzymes with the ability to reduce organic and inorganic hydroperoxides to the corresponding alcohols using glutathione or thioredoxin as an electron donor. These enzymes promote hydrogen peroxide metabolism and protect cell membrane structure and function from oxidative damage. Dysregulated GPx expression is connected with severe pathologies, including obesity and diabetes. GPx1 has been reported to be involved in both pro- and anticancer effects in different tumor models.

In mammals, the GPxs family consists of eight members (GPx1-GPx8) identified so far; five of them (GPx1-GPx4 and GPx6) contain selenocysteine in the catalytic center and the other three are cysteine-containing proteins. GPx1 is one of the most critical members of the GPxs family that catalytically reduces hydrogen peroxide to produce water. The function of GPx3 is to scavenge H2O2 and lipoperoxides in the plasma to reduce systematic oxidative stress and to maintain the bioavailability of vascular nitric oxide. Gpx4 is an essential mammalian glutathione peroxidase, which protects cells against detrimental lipid peroxidation and governs a novel form of regulated necrotic cell death, called ferroptosis.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-13679R
    Sodium 2-mercaptoethanesulfonate (Standard)
    Sodium 2-mercaptoethanesulfonate (Standard) is the analytical standard of Sodium 2-mercaptoethanesulfonate. This product is intended for research and analytical applications. Mesna (Sodium 2-mercaptoethanesulfonate) is an antioxidant which has cytoprotective effects. Mesna is widely used as a systemic protective agent against chemotherapy toxicity. Mesna is also used to reduce hemorrhagic cystitis induced by cyclophosphamide.
    Sodium 2-mercaptoethanesulfonate (Standard)
  • HY-169133
    GDCNF-11
    		Degrader
    GDCNF-11 is a HIM-PROTAC GPX4 degrader based on the chaperone protein HSP90. GDCNF-11 promotes the ubiquitination and degradation of GPX4 through the HSP 90 chaperone complex, reduces endogenous GPX4 expression to induce ferroptosis in HT-1080 cells, and the DC50 value is 0.08 μM (Pink: Target protein ligand (HY-153748); Blue: HSP90 ligand (HY-10212); Black: Linker (HY-W169526)).
    GDCNF-11
  • HY-W001083R
    3-Hydroxyphenylacetic acid (Standard)
    		Activator
    3-Hydroxyphenylacetic acid (Standard) is the analytical standard of 3-Hydroxyphenylacetic acid (HY-W001083). This product is intended for research and analytical applications. 3-Hydroxyphenylacetic acid is an orally active flavonoid metabolite produced by intestinal flora, with blood pressure-lowering activity. 3-Hydroxyphenylacetic acid can also inhibit ferroptosis by upregulating the expression of GPX4, thereby improving spermatogenic dysfunction in aged mice. In addition, abnormal levels of 3-Hydroxyphenylacetic acid are closely related to certain diseases, such as autism spectrum disorders.
    3-Hydroxyphenylacetic acid (Standard)
  • HY-162106
    PROTAC GPX4 degrader-2
    		Degrader
    PROTAC GPX4 degrader-2 (compound 18a) is a proteolysis targeting chimeras (PROTACs) that can degrade glutathione peroxidase 4 (GPX4), with the DC50, 48h value of 1.68 μM. PROTAC GPX4 degrader-2 induces the accumulation of lipid peroxides and mitochondrial depolarization, subsequently triggering ferroptosis. PROTAC GPX4 degrader-2 has anti-proliferative effect.
    PROTAC GPX4 degrader-2
  • HY-175826
    USP30-IN-20
    		Degrader
    USP30-IN-20 is an orally active USP30 inhibitor (Kd = 1.61 μM, IC50 = 12.8 μM). USP30-IN-20 induces ferroptosis by promoting ubiquitination-mediated degradation of GPX4. USP30-IN-20 inhibits the proliferation, migration, invasion, and stemness of prostate cancer cells. USP30-IN-20 induces G0/G1 cell cycle arrest and ROS levels in prostate cancer cells. USP30-IN-20 exhibits significant anti-tumor efficacy in PC3 cell subcutaneous xenografts in mice. USP30-IN-20 can be used for the study of advanced prostate cancer.
    USP30-IN-20
  • HY-N0171AR
    Beta-Sitosterol (purity>98%) (Standard)
    		Agonist
    Beta-Sitosterol (purity>98%) (Standard) is an analytical standard for Beta-Sitosterol (purity>98%). Beta-Sitosterol (purity>98%) is intended for research and analytical applications. Beta-Sitosterol (purity>98%) is orally active. Beta-Sitosterol exhibits multiple activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, antioxidant enzyme, and analgesic. Beta-Sitosterol inhibits inflammation and impaired adipogenesis in bovine mammary epithelial cells by reducing levels of ROS, TNF-α, IL-1β, and NF-κB p65 and restoring the activity of the HIF-1α/mTOR signaling pathway. Beta-Sitosterol induces apoptosis in cancer cells through ROS-mediated mitochondrial dysregulation and p53 activation. Beta-Sitosterol exerts its anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, altered Bcl-2-Bax ratio, and cytochrome c release. Beta-Sitosterol modulates macrophage polarization and reduces rheumatoid inflammation in mice. Beta-Sitosterol inhibits tumor growth in multiple mouse cancer models. Beta-Sitosterol can be used in the research of arthritis, lung cancer, breast cancer and other cancers, diabetes, etc.
    Beta-Sitosterol (purity>98%) (Standard)
  • HY-177483
    OART
    		Inhibitor
    OART (Oxaliplatin-artesunate) is a ferroptosis inducer. OART significantly inhibits tumor cell proliferation. OART induces cytoplasmic and mitochondrial LPO to promote tumor ferroptosis, via destroying glutathione-mediated ferroptosis defense system and enhancing iron-dependent Fenton reaction. OART enhances tumor immunogenicity, transforming tumor environment from immunosuppressive to immunosensitive. OART has strong tumor regression in tumor-bearing mouse models. OART can be used for cancer immunotherapy research.
    OART
  • HY-125859E
    Myeloperoxidase, Human Neutrophil
    Myeloperoxidase, Human Neutrophil is a peroxidase. Myeloperoxidase, Human Neutrophil is a potent antibacterial agent by catalyzing the H2O2-dependent oxidation of chloride anion to generate hypochlorous acid. Myeloperoxidase, Human Neutrophil catalyzes the degradation of N-retinyl-idene-N-retinylethanolamine, a toxic form of retinal lipofuscin. Myeloperoxidase, Human Neutrophil also triggers lysosomal stress and cell death. Myeloperoxidase, Human Neutrophil can be used for the researches of inflammation and infection.
    Myeloperoxidase, Human Neutrophil
  • HY-163335
    MPO-IN-7
    		Inhibitor
    MPO-IN-7 (compound MDC) is a myeloperoxidase inhibitor with the IC50 values of 41 μM, 25 μM and 4.5 μM towards α-Glucosidase, dipeptidyl peptidase-4 and myeloperoxidase, respectively. MPO-IN-7 shows antioxidant and anti-inflammatory activity in vitro.
    MPO-IN-7
  • HY-178475
    CA IX/GPX4-IN-1
    		Inhibitor
    CA IX/GPX4-IN-1 (Compound 22abcb) is a dual targeted inhibitor of CA IX and GPX4 activity. CA IX/GPX4-IN-1 can effectively kill SUM159PT cells (IC50 = 416 nM) by inducing iron death under hypoxic conditions. CA IX/GPX4-IN-1 has an IC50 of 663 nM to CA IX in SUM159PT-CAIX-FL cells. CA IX/GPX4-IN-1 can significantly inhibit tumor growth and can be reversed by ferroptosis inhibitors. CA IX/GPX4-IN-1 can be used for research on breast cancer and other cancers.
    CA IX/GPX4-IN-1
  • HY-176220
    GPX4-AUTAC
    		Degrader
    GPX4-AUTAC is a GPX4-targeting autophagy-mediated degrader (AUTAC). GPX4-AUTAC consists of an inhibitor ML162-yne (HY-153748), a degradation tag FBnG (HY-W073762) and a glycol linker (HY-W021401). GPX4-AUTAC promotes the ubiquitination of GPX4 by E3 ligase TRAF6, and enhances the binding with GPX4 and p62, leading to the selective autophagy-dependent degradation of GPX4. GPX4-AUTAC significantly induces ferroptosis and shows a potent anti-cancer activity in breast cancer cells, breast cancer-derived organoids (PDOs) and MDA-MB-231 tumor xenograft mice model, with potent synergistic effects when combined with Sulfasalazine (SAS) (HY-14655) or chemotherapy drugs (Paclitaxel (HY-B0015) or Cisplatin (HY-17394)).
    GPX4-AUTAC
  • HY-178115
    MB-Buf
    		Degrader
    MB-Buf is a conjugation of methylene blue (HY-14536) and bufalin (HY-N0877) . MB-Buf can targeting degrade GPX4 upon light activation. MB-Buf can induce cell apoptosis, ferroptosis, and ROS production. MB-Buf can be used for the research of cancer, such as breast cancer.
    MB-Buf
  • HY-146651
    MPO-IN-4
    		Inhibitor
    MPO-IN-4 (compound 12) is a potent and selective myeloperoxidase (MPO) inhibitor with an IC500 of 25 nM. MPO-IN-4 has no effect on methyl guanine methyl transferase (MGMT).
    MPO-IN-4
  • HY-159483
    SelB-1
    		Inhibitor
    SelB-1 serves as a dual inhibitor for Topoisomerase I/II. SelB-1 possesses anticancer activity and can be utilized in the research of prostate cancer and colon cancer. Furthermore, SelB-1 is also capable of inducing autophagy gene expression and lipid peroxidation, while simultaneously reducing the level of GSH.
    SelB-1
  • HY-173408
    Nur77 agonist-1
    		Inhibitor
    Nur77 agonist-1 (Compound 8f) is an orally active Nur77 agonist. Nur77 agonist-1 induces ferroptosis by upregulating Nur77 protein expression, increasing reactive oxygen species (ROS) and lipid peroxidation levels, and decreasing GPX4 protein expression. Nur77 agonist-1 has binding affinity to the ligand binding domain (LBD) of Nur77 (KD: 13.80 μM). Nur77 agonist-1 exhibits significant antiproliferative activity against a variety of breast cancer cells (IC50: 2.15-3.26 μM) and has low toxicity to normal cells. Nur77 agonist-1 can be used in breast cancer research.
    Nur77 agonist-1
  • HY-139008
    RC363
    		Activator
    RC363 is a novel probucol analog with the activity to protect mouse hippocampal cells and primary cortical neurons from glutamate-induced oxidative cell death (ferroptosis) and increase glutathione peroxidase (GPx) 1 levels and activity.
    RC363
  • HY-168879
    GPX4-IN-16
    		Inhibitor
    GPX4-IN-16 ((R)-9i) is a potent GPX4 inhibitor with an Kd value of 20.4 nM. GPX4-IN-16 shows cytotoxicity. GPX4-IN-16 shows anticancer activity.
    GPX4-IN-16
  • HY-139012
    RC574
    RC574 is a novel probucol analog with the activity to protect mouse hippocampal cells and primary cortical neurons from glutamate-induced oxidative cell death (ferroptosis) and increase glutathione peroxidase (GPx) 1 levels and activity.
    RC574
  • HY-162717
    GPX4-IN-11
    		Inhibitor
    GPX4-IN-11 (compound I14) is a potent inhibitor of GPX4, with the KD of 45.7 μM. GPX4-IN-11 plays an important role in ferroptosis research.
    GPX4-IN-11
  • HY-175811
    Ferroptosis inducer-10
    		Inhibitor
    Ferroptosis inducer-10 is a ferroptosis inducer. Ferroptosis inducer-10 can inhibit A549 cells growth with an IC50 of 0.76 μM. Ferroptosis inducer-10 can deplete GSH, elevate ROS and MDA, and downregulate GPX4 expression. Ferroptosis inducer-10 can induce cell G2/M phase and inhibit migration. Ferroptosis inducer-10 can be used for the research of cancer, such as non-small lung cancer.
    Ferroptosis inducer-10
Cat. No. Product Name / Synonyms Application Reactivity